Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DW1807
- Development stage
- Phase 3
- Lead developer
- Daewon Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DW1807 is a Daewon Pharm fixed-dose combination modified drug candidate being evaluated for perennial allergic rhinitis in adults with comorbid asthma. A randomized, double-blind, active-controlled Phase 3 study compares DW1807 with DW1807-R2 over four weeks, with improvement in reflective total nasal symptom score as the primary efficacy objective. Public trial materials do not disclose DW1807's active ingredients, molecular targets, dosage form, route, or detailed mechanism of action. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07168473))
- Other names
- levodropropizine + bromhexinelevodropropizine/bromhexine combination
02
Targets
ADRA1A (α1A)HRH1 (Histamine H1 Receptor)VAMP (SNARE Protein Complex)ADRA1 (Alpha-1 adrenergic receptor family)MUC2 (Mucin-2)TMPRSS2 (Transmembrane protease serine 2)
Beyond the preview
Go deeper on DW1807.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DW1807.